1. Алексеева Н.С. Клиническая эффективность препарата Бетасерк. Междунар. мед. новости. 2001; 3: 21–5.
2. Веселаго О.В. Опыт применения Тагисты в лечении вестибулярных расстройств при хронической недостаточности мозгового кровообращения. Рус. мед. журн. 2010; 26: 1546–50.
3. Гусев Е.И., Никонов А.А., Скворцова В.И. и др. Лечение головокружений препаратом Бетасерк у больных с сосудистыми и травматическими поражениями головного мозга. Журн. неврологии и психиатрии. 1998; 11: 45–50.
4. Никифоров А.С., Коновалов А.Н., Гусев Е.И. Клиническая неврология. М.: Медицина, 2002.
5. Табеева Г.Р., Вейн А.М. Головокружение при психовегетативных синдромах. Cons. Med. 2001; 4 (15): 41–6.
6. Шеремет А.С. Головокружение как признак поражения вестибулярного анализатора. Диагностические стереотипы. Cons. Med. Отоларингология. 2001; 04: 15–20.
7. Aantaa E. Treatment of acute vestibular vertigo. Acta Otolaryngol. (Stockh). 1991; Suppl. 479: 44–7.
8. Ahn S, Balaban C. Distribution of 5-HT1B and 5-HT1D receptors in the inner ear. Brain Res 2010; 1346: 92–101.
9. Alvarenga G., Barbosa M., Porto C. Benign paroxysmal positional vertigo without nystagmus: diagnosis undtreatment. Braz J Otorhinolaryngol 2001; 77 (6): 799–804.
10. Albera R, Ciuffolotti R, Di Cicco M. Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. Acta Otolaryngol 2003; 123 (5): 588–93.
11. Baloh R. Dizziness, hearing loss, and tinnitus. New York: Oxford University Press, 1998; 107–25.
12. Brandt T, Kapfhammer H. Dieterich M. Phobic postural vertigo. A further differentiation of psychogenic vertigo conditions seems necessary. Nervenarzt 1997; 68 (10): 848–9.
13. Brevern M, Radtke A, Lezius F et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry 2007; 78: 710–5.
14. Cavaliere M, Mottola G, Iemma M. Benign paroxysmal positional vertigo: a study of two maneuvers with and without betahistine. Acta Otorhinolaryngol Ital 2005; 25 (2): 107–12.
15. Chang C-C, Chang W-N, Huang C-R et al. The Relationship between Isolated Dizziness/Vertigo and the Risk Factors of Ischemic Stroke: A Case Control Study. Acta Neurol Taiwan 2011; 20: 101–6.
16. Chávez H, Vega R, Valli P et al. Action mechanism of betahistine in the vestibular end organs. Acta Otorhinolaryngol Ital 2001; 21 (3 Suppl. 66): 8–15.
17. Claes J, Van De Heyning PH. A review of medical treatment for Meniere's disease Acta Oto-laryngol. (Stickh.) 2000; Suppl. 544: 34–9.
18. Colledge N, Wilson J, Macintyre C, MacLennan W. The prevalence and characteristics of dizziness in an elderly community. Age Aging 1994; 23: 117–20.
19. Drachman D, Hart C. An approach to the dizzy patient. Neurology 1972; 22: 323–34.
20. Dutia M. Betahistine, vestibular function and compensation: in vitro studies of vestibular function and plasticity. Acta Otolaryngol Suppl 2000; 544: 11–4.
21. Fraysse B, Bebear J, Dubreuil C. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Menière's disease. Acta Otolaryngol Suppl 1991; 490: 1–6.
22. Gbahou F, Davenas E, Morisset S, Arrang M. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther 2010; 334 (3): 945–54.
23. Gil-Loyzaga P. Neurotransmitters of the olivocochlear lateral efferent system: with an emphasis on dopamine. Acta Otolaryngol 1995; 115 (2): 222–6.
24. Halmagyi G. Diagnosis and management of vertigo. Clin Med 2005; 5 (2): 159–65.
25. Han B, Song H, Kim J. Vestibular Rehabilitation Therapy: Review of Indications, Mechanisms, and Key Exercises. J Clin Neurol 2011; 7 (4): 184–96.
26. Johkura K. Dizziness/vertigo caused by small cerebellar/brainstem strokes. Rinsho Shinkeigaku 2011; 51 (11): 1092–5.
27. Kammerlind A, Hakansson J, Skogsberg M. Effects of balance training in elderly people with nonperipheral vertigo and unsteadiness. Clin Rehabil 2001; 15 (5): 463–70.
28. Lai Y, Wang T, Chuang L et al. Epidemiology of vertigo: a National Survey. Otolaryngol Head Neck Surg 2011; 145 (1): 110–6.
29. Lucertini M, Lugli V. The Italian Air Force rehabilitation programme for air-sickness. Acta Otorhinolaryngol Ital 2004; 24 (4): 181–7.
30. Mira E, Guidetti G, Ghilardi L. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol 2003; 260 (2): 73–7.
31. Mohamed E, Kaf W, Rageh T et al. Evaluation of patients with vertigo of vertebrobasilar insufficiency origin using auditory brainstem response, electronystagmography, and transcranial Doppler. Int J Audiol 2012 [Epub ahead of print].
32. Rascol O, Hain T, Brefel C et al. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs 1995; 50 (5): 777–91.
33. Serafin M, Khateb A, Vibert N et al. Medial vestibular nucleus in the guinea-pig: histaminergic receptors. I. An in vitro study. Exp Brain Res 1993; 93 (2): 242–8.
34. Soto-Varela A, Rossi-Izquierdo M, Martínez-Capoccioni G et al. Benign paroxysmal positional vertigo of the posterior semicircular canal: efficacy of Santiago treatment protocol, long-term follow up and analysis of recurrence. J Laryngol Otol 2012; 6: 1–9.
35. Staab J. Behavioral aspects of vestibular rehabilitation. NeuroRehabilitation 2011; 29 (2): 179–83.
36. Strupp M, Brandt T. Diagnosis and treatment of vertigo and dizziness. Dtsch Arztebl Int 2008; 105 (10): 173–80.
37. Tighilet B, Leonard J, Lacour M. Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat. J Vest Res 1995; 5: 53–66.

П.Р.Камчатнов 

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ